A large study has found no improvement in overall survival using a combination chemo-immunotherapy regimen for metastatic renal cell carcinoma, compared with immunotherapy alone. While the development of targeted therapies has provided uro-oncologists with a wider variety of treatment options, immunotherapy retains an important role in the management of metastatic renal cell carcinoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gore, M. E. et al. Interferon α-2a versus combination therapy with interferon α-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375, 641–648 (2010).
Atzpodien, J. et al. IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130–1136 (2001).
Négrier, S. et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon α with or without fluorouracil. J. Clin. Oncol. 18, 4009–4015 (2000).
[No authors listed]. Interferon-α and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353, 14–17 (1999).
Escudier, B. et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).
Escudier, B. et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon α-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280–1289 (2009).
Di Lorenzo, G., Autorino, R. & Sternberg, C. N. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur. Urol. 56, 959–971 (2009).
Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).
Atkins, M. et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin. Cancer Res. 11, 3714–3721 (2005).
Atkins, M. B., Choueiri, T. K., Cho, D., Regan, M. & Signoretti, S. Treatment selection for patients with metastatic renal cell carcinoma. Cancer 115 (10 Suppl.), 2327–2333 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Autorino, R., Di Lorenzo, G. An evolving role for immunotherapy in metastatic RCC. Nat Rev Urol 7, 305–307 (2010). https://doi.org/10.1038/nrurol.2010.64
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2010.64